Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
Randomized phase III, multicentre, open label clinical trial to compare pevonedistat in combination with azacytidine versus azacytidine alone, which can be considered a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy (thus not eligible for an allogeneic hematopoietic stem cell transplant.
Epistemonikos ID: bcdc624c3ebf2deeb0988c7b42dd74c8037346c0
First added on: Jan 21, 2022